Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 1 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Acquired Immunodeficiency… | 1 |
| Child Development | 1 |
| Children | 1 |
| Clinical Diagnosis | 1 |
| Correlation | 1 |
| Drug Therapy | 1 |
| Genetics | 1 |
| Medical Research | 1 |
| Metabolism | 1 |
| Neurology | 1 |
| Outcomes of Treatment | 1 |
| More ▼ | |
Author
| Bowers, Megan | 1 |
| Grigorenko, Elena L. | 1 |
| Tan, Mei | 1 |
| Thuma, Phil | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Descriptive | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkTan, Mei; Bowers, Megan; Thuma, Phil; Grigorenko, Elena L. – New Directions for Child and Adolescent Development, 2020
Efavirenz (EFV) is a well-known, effective anti-retroviral drug long used in first-line treatment for children and adults with HIV and HIV/AIDS. Due to its narrow window of effective concentrations, between 1 and 4 µg/mL, and neurological side effects at supratherapeutic levels, several investigations into the pharmacokinetics of the drug and its…
Descriptors: Drug Therapy, Outcomes of Treatment, Acquired Immunodeficiency Syndrome (AIDS), Neurology
